)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
uniQure
uniQure (QURE) investor relations material
uniQure Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
FDA accepted the AMT-130 BLA for Priority Review under the Accelerated Approval pathway, with a May 1, 2027 PDUFA target; the U.K. MHRA validated the MAA.
September 30 liquidity was $768.4M in cash, cash equivalents and investment securities, or $770.0M including restricted cash; projected operations are expected to be funded into 2030.
Financial highlights
Q3 revenue was $5.2M vs. $3.7M; 9M revenue was $14.6M vs. $10.5M, primarily from license royalties on HEMGENIX® sales.
Q3 R&D was $35.5M vs. $34.4M and SG&A was $23.9M vs. $19.4M; 9M R&D was $98.7M vs. $105.9M and SG&A was $61.4M vs. $43.8M.
Q3 net loss narrowed to $61.2M from $80.5M, or $0.88 vs. $1.38 per share; 9M net loss widened to $195.8M from $161.9M.
Q3 operating loss was $53.0M vs. $51.0M; 9M operating loss was $150.9M vs. $134.2M.
Higher personnel, professional fees and IT costs supported commercial readiness; 9M operating cash use was $114.6M vs. $100.4M.
Outlook and guidance
AMT-130 confirmatory-study screening is targeted by year-end 2026; the global study plans ~200 patients randomized 2:1 to high-dose AMT-130 or standard of care, with TFC at 36 months as the primary endpoint.
Updated AMT-260 and AMT-191 data are expected in H1 2027; the core commercial team is expected to be in place by early 2027.
Field medical, market access and strategic account teams are being built ahead of a potential AMT-130 launch; no specific SG&A guidance was given, with spending expected to rise under a disciplined approach.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from uniQure
- AMT-130 showed 80% cUHDRS slowing at 36 months and 61% TFC slowing at 48 months.QURE
Study update - AMT-130 BLA filing on track; $811.9M cash funds operations into 2030; pipeline shows promise.QUREQ2 2026
- Q1 2026 brought higher revenue, a $53.5M net loss, and key regulatory and pipeline milestones.QUREQ1 2026
- Shareholders will vote on governance, compensation, capital structure, and policy changes.QUREProxy filing
- Key votes include director reappointments, auditor selection, and amendments to governance and share capital.QUREProxy filing
- Shareholders will vote on director reappointments, compensation, auditor, and key governance changes.QUREProxy filing
- FDA alignment enables accelerated approval using Phase I/II data and cUHDRS as an endpoint.QUREStudy Update
- AMT-130 slowed disease progression by 80% and reduced neurodegeneration biomarkers at 24 months.QUREStudy Update
- FDA alignment enables AMT-130 BLA submission in Q1 2026, using Enroll-HD as external control.QUREStatus Update
Next uniQure earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
uniQure
Next uniQure earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
uniQure N.V. is a biotechnology company that develops gene therapies for the treatment of genetic diseases. The company uses viral vector platforms to deliver therapeutic genes to targeted tissues. It focuses on research, clinical development, and manufacturing of gene-based treatments. The company is headquartered in Amsterdam, Netherlands, and its shares are listed on the NASDAQ.